Synthesis and in vitro evaluation of imidazopyridazines as novel inhibitors of the malarial kinase PfPK7

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 19, 2008, Pages 5294-5298

  Bouloc, Nathalie ^a   Large, Jonathan M ^a   Smiljanic, Ela ^a   Whalley, David ^a   Ansell, Keith H ^a   Edlin, Christopher D ^a   Bryans, Justin S ^a  

^a Centre for Therapeutics Discovery   (United Kingdom)

Author keywords

Imidazopyridazines; Kinase inhibitors; Malaria

Indexed keywords

CHLOROQUINE; IMIDE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN PFPK7; PYRIDAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; IC 50; IN VITRO STUDY; NONHUMAN; PLASMODIUM FALCIPARUM; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMALARIALS; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; KB CELLS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR STRUCTURE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; PYRIDAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 52049124549     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.08.043     Document Type: Article

References (18)

1. Ridley R.G. Microbes Infect. 4 (2002) 155
2. Renslo A.R., and McKerrow J.H. Nat. Chem. Biol. 2 (2006) 701
3. Ward P., Equinet L., Packer J., and Doerig C. BMC Genomics 5 (2004) 79
4. Anamika, Srinivasan N., and Krupa A. Proteins 58 (2005) 180
5. Pattanaik P., Raman J., and Balaram H. Curr. Top. Med. Chem. 2 (2002) 483
6. Doerig C., Billker O., Pratt D., and Endicott J. Biochim. Biophys. Acta 1754 (2005) 132
7. Kissinger J.C., Brunk B.P., Crabtree J., Fraunholz M.J., Gajria B., Milgram A.J., Pearson D.S., Schug J., Bahl A., Diskin S.J., Ginsburg H., Grant G.R., Gupta D., Labo P., Li L., Mailman M.D., McWeeney S.K., Whetzel P., Stoeckert Jr. C.J., and Roos D.S. Nature 419 (2002) 490
8. Dorin D., Semblat J.P., Poullet P., Alano P., Goldring J.P., Whittle C., Patterson S., Chakrabarti D., and Doerig C. Mol. Microbiol. 55 (2005) 184
9. Merckx A., Echalier A., Langford K., Sicard A., Langsley G., Joore J., Doerig C., Noble M., and Endicott J. Structure 16 (2008) 228
10. Byth K.F., Cooper N., Culshaw J.D., Heaton D.W., Oakes S.E., Minshull C.A., Norman R.A., Pauptit R.A., Tucker J.A., Breed J., Pannifer A., Rowsell S., Stanway J.J., Valentine A.L., and Thomas A.P. Bioorg. Med. Chem. Lett. 14 (2004) 2249
11. +, 100%).
12. +, 100%).
13. For example, the CDK inhibitor purvalanol A bears such an amino alcohol substituent. Gray N.S., Wodicka L., Thunnissen A.-M.W.H., Norman T.C., Kwon S., Espinoza F.H., Morgan D.O., Barnes G., LeClerc S., Meijer L., Kim S.-H., Lockhart D.J., and Schultz P.G. Science 281 (1998) 533
14. Miyaura N., Maeda K., and Suginome H. J. Org. Chem. 47 (1982) 2117
15. For a recent review of chiral sulfinimine chemistry see. Morton D., and Stockman R.A. Tetrahedron 62 (2006) 8869
16. Too K., Brown D.M., Bongard E., Yardley V., Vivas L., and Loakes D. Bioorg. Med. Chem. 15 (2007) 5551
17. Dorin-Semblat D., Sicard A., Doerig C., Ranford-Cartwright L., and Doerig C. Eukaryot. Cell 7 (2008) 279
18. Graczyk P.P. J. Med. Chem. 50 (2007) 5773